Additionally, other recent studies convincingly demonstrate that BET inhibitors can prevent transcriptional reprogramming triggered by numerous kinase inhibitors, which leads to improved efficacy in preclinical models of solid tumors, such as breast cancer and melanoma43,44, thus suggesting the use of BET inhibitors in combination with kinase inhibitors. The gene discussed is DNER; the disease is breast carcinoma.